Literature DB >> 11907519

Transfer of vitiligo after allogeneic bone marrow transplantation.

Abdulmajeed Alajlan1, Abdullah Alfadley, Kristian-Thestrup Pedersen.   

Abstract

Adoptive transfer of donor immunity has been demonstrated in animals after bone marrow transplantation (BMT). In humans, several autoimmune diseases have been similarly transferred. Although BMT may, per se, be associated with a modulation of the recipient's immune system, which could trigger or even cause autoimmune diseases, both animal experiments and experience with humans show the likeliness of adoptive transfer of donor immunity to the recipient. We describe a patient with multiple myeloma in whom generalized vitiligo developed within 3 months after allogeneic BMT from his HLA-matched sister with vitiligo. We believe that a form of adoptive transfer of donor immunity to the recipient might play a role in the development of vitiligo. In spite of this, neither de novo development of vitiligo in a genetically predisposed patient nor autoimmune phenomena associated with graft-versus-host disease can be completely excluded as a contributing factor for development of vitiligo in our patient. To our knowledge, this is the first case report of transfer of vitiligo after BMT from a donor with vitiligo.

Entities:  

Mesh:

Year:  2002        PMID: 11907519     DOI: 10.1067/mjd.2002.117215

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

Review 1.  Vitiligo following stem-cell transplant.

Authors:  Alessio Totani; Hossam Amin; Stephen Bacchi; Ian Lewis
Journal:  Bone Marrow Transplant       Date:  2019-07-29       Impact factor: 5.483

Review 2.  Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo.

Authors:  John E Harris
Journal:  Immunol Rev       Date:  2016-01       Impact factor: 12.988

3.  Frontiers and controversies in the pathobiology of vitiligo: separating the wheat from the chaff.

Authors:  Raymond E Boissy; Richard A Spritz
Journal:  Exp Dermatol       Date:  2009-03-06       Impact factor: 3.960

4.  Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease.

Authors:  Rena C Zuo; Haley B Naik; Seth M Steinberg; Kristin Baird; Sandra A Mitchell; Zoya Kuzmina; Steven Z Pavletic; Edward W Cowen
Journal:  JAMA Dermatol       Date:  2015-01       Impact factor: 10.282

5.  Use of ultraviolet-light irradiated multiple myeloma cells as immunogens to generate tumor-specific cytolytic T lymphocytes.

Authors:  Charles A Gullo; William Yk Hwang; Chye K Poh; Melvin Au; Geraline Cow; Gerrard Teoh
Journal:  J Immune Based Ther Vaccines       Date:  2008-04-28

6.  Severe chronic psychosis after allogeneic SCT from a schizophrenic sibling.

Authors:  I E Sommer; D W van Bekkum; H Klein; R Yolken; Lot de Witte; G Talamo
Journal:  Bone Marrow Transplant       Date:  2014-10-06       Impact factor: 5.483

7.  High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease.

Authors:  Romana Čeović; Lana Desnica; Dražen Pulanić; Ranka Serventi Seiwerth; Ivana Ilić; Magdalena Grce; Marinka Mravak Stipetić; Tajana Klepac Pulanić; Ervina Bilić; Ernest Bilić; Milan Milošević; Radovan Vrhovac; Damir Nemet; Steven Z Pavletic
Journal:  Croat Med J       Date:  2016-06-30       Impact factor: 1.351

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.